A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is
Case Report Beneficial effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors, a new class of oral antidiabetic medications, have been shown in patients with type 2 diabetes and subsequently with type 1 diabetes. Since SGLT2 inhibitors lower blood glucose levels by increasing urinary glucose excretion, insulin doses often need to be reduced to avoid hypoglycemia, leading to increased ketone body formation and, possibly, euglycemic diabetic ketoacidosis. In this case report, we present adoi:10.36347/sjmcr.2020.v08i11.008 fatcat:pslvcearejgjdmk3w7wdwejguy